Phase 1 trial of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2-T cell engager, in patients with CD123 positive relapsed/refractory (R/R) acute myeloid leukemia (AML) and intermediate risk, high risk, or extremely high-risk myelodysplastic syndrome (MDS)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518831-12-00

Acronym

LAVA1266-001

Enrollment

Registered

2025-03-19

Start date

2025-04-15

Completion date

2025-08-04

Last updated

2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD123 positive R/R AML and intermediate risk, high risk, or extremely high risk MDS.

None listed

Sex/Gender

All

Age

18 Years to No maximum

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026